

Efferon[®] NEO

Next-generation hemoadsorption for the most fragile patients



Next-generation hemoadsorption device for endotoxin and cytokine removal



For patients with lower circulating blood volume



For isolated hemoadsorption or in combination with RRT, ECMO/CPB



Blood priming volume, 30 mL



Approved for sepsis and septic shock

CE marked under the EU MDR




Designed and Manufactured in the European Union

Pediatric sepsis remains a critical challenge

Children with sepsis are among the most vulnerable ICU patients.

MECHANISM OF ACTION

Endotoxins are bound due to interaction with surface-immobilized LPS-selective ligand



40%

all sepsis cases worldwide occur in children under 5 years of age

20M

cases of sepsis annually


Effective modulation of systemic inflammation is essential to improve outcomes.

CLINICAL EVIDENCE: LASSO NEO MULTICENTER STUDY¹


STUDY DESIGN

- 8 study centers
- 78 low-volume patients (32 Hemoadsorption group vs. 46 historical control group)
- Weight, kg Median (IQR): Hemoadsorption group 12 (9; 18) vs. control group 15 (11; 22), $p = 0.091$
- Hemoadsorption × 2 sessions / 18 hours total

Reduction of inflammatory markers within hemoadsorption group, Day 1 vs. Day 2



Earlier weaning from organ support




MAIN OUTCOMES

Lower 28-day mortality (OR = 0.2 (95%CI 0.05–0.74), $p = 0.008$)


9%
in
hemoadsorption
group

35%
in
control group

Lower pSOFA score by day 7



Vasopressor/inotropic support



1 - LIVES 2025. ICMx 13 (Suppl 1), 109 (2025), p. 395–396 <https://doi.org/10.1186/s40635-025-00797-x>

Efferon OÜ
Harju maakond, Tallinn,
Kristiine linnaosa,
Mooni tn 18, 10613, Estonia

CE 2265

Distributed by:
NORRDIA
NorrDia Belgium bv
Industriepark 6
3300 Tienen
Belgium

www.norrdia.com